Dữ liệu mới nổi về các biến thể cắt ghép thụ thể androgen trong ung thư tiền liệt tuyến

10.1016/j.cell.2015.10.025

10.1111/j.1432-1033.2004.04395.x

10.1210/me.2009-0188

10.1016/j.ccr.2010.04.027

10.1001/jamaoncol.2015.1341

10.1056/NEJMoa1315815

10.1038/nature13229

10.1200/JCO.2007.15.9749

10.1158/0008-5472.CAN-08-3667

10.1038/onc.2009.243

10.1002/pros.22649

10.18632/oncotarget.2924

Cao, 2013, 20(S)-protopanaxadiol-aglycone downregulation of the full-length and splice variants of androgen receptor, International Journal of Cancer, 132, 1277, 10.1002/ijc.27754

10.18632/oncotarget.1802

Chan, 2014, Constitutive activity of the androgen receptor, Advances in Pharmacology, 70, 327, 10.1016/B978-0-12-417197-8.00011-0

10.1074/jbc.M112.352930

10.1093/nar/gkv262

Chen, 2010, Hedgehog/Gli supports androgen signaling in androgen deprived and androgen independent prostate cancer cells, Molecular Cancer, 9, 89, 10.1186/1476-4598-9-89

10.1038/emboj.2011.154

10.1371/journal.pone.0063466

10.1074/jbc.M114.553818

10.1158/0008-5472.CAN-11-1417

10.1056/NEJMoa1014618

10.1158/1078-0432.CCR-14-1358

10.1158/0008-5472.CAN-08-0594

10.1158/0008-5472.CAN-06-0411

10.1200/JCO.2010.33.7675

10.1016/j.eururo.2014.05.005

10.1016/j.ctrv.2013.09.011

10.1074/jbc.M610447200

10.1158/0008-5472.CAN-15-2186

10.1016/S1470-2045(12)70379-0

10.1200/JCO.2002.10.018

10.1158/0008-5472.CAN-08-3795

10.1021/jm040202w

10.1073/pnas.1421415111

10.1371/journal.pone.0019059

10.1158/0008-5472.CAN-08-2764

10.1002/pros.21382

10.1158/0008-5472.CAN-11-3892

10.1210/en.2007-0446

Kahn, 2014, Androgen receptor as a driver of therapeutic resistance in advanced prostate cancer, International Research Journal of Biological Sciences, 10, 588, 10.7150/ijbs.8671

Karaca, 2015, Mutation of androgen receptor N-terminal phosphorylation site Tyr-267 leads to inhibition of nuclear translocation and DNA binding, PLoS ONE, 10, e0126270, 10.1371/journal.pone.0126270

10.1158/1078-0432.CCR-15-2119

10.1158/1078-0432.CCR-08-2660

Kwegyir-Afful, 2015, Galeterone and VNPT55 induce proteasomal degradation of AR/AR-V7, induce significant apoptosis via cytochrome c release and suppress growth of castration resistant prostate cancer xenografts in vivo, Oncotarget, 6, 27440, 10.18632/oncotarget.4578

10.1158/0008-5472.CAN-10-1998

Li, 2014, Discovery of small-molecule inhibitors selectively targeting the DNA-binding domain of the human androgen receptor, Journal of Medicinal Chemistry, 57, 6458, 10.1021/jm500802j

Li, 2014, Determinants of Gli2 co-activation of wildtype and naturally truncated androgen receptors, Prostate, 74, 1400, 10.1002/pros.22855

10.1158/0008-5472.CAN-12-3630

10.1371/journal.pone.0031213

10.1038/onc.2011.637

Li, 2015, Catalytic inhibitors of DNA topoisomerase II suppress the androgen receptor signaling and prostate cancer progression, Oncotarget, 6, 20474, 10.18632/oncotarget.4105

Li, 2015, AR-v7 protein expression is regulated by protein kinase and phosphatase, Oncotarget, 6, 33743, 10.18632/oncotarget.5608

Liu, 2016, Niclosamide enhances abiraterone treatment via inhibition of androgen receptor variants in castration resistant prostate cancer, Oncotarget, 7, 32210, 10.18632/oncotarget.8493

10.1158/0008-5472.CAN-08-2038

10.1002/pros.23015

Liu, 2015, MED1 mediates androgen receptor splice variant induced gene expression in the absence of ligand, Oncotarget, 6, 288, 10.18632/oncotarget.2672

10.1158/1078-0432.CCR-13-3296

10.1038/onc.2013.284

10.1593/neo.13784

Lu, 2014, The cistrome and gene signature of androgen receptor splice variants in castration-resistant prostate cancer cells, Journal of Urology, 193, 690, 10.1016/j.juro.2014.08.043

Lu, 2015, Are androgen receptor variants a substitute for the full-length receptor?, Nature Reviews Urology, 12, 137, 10.1038/nrurol.2015.13

Martin, 2015, N-terminal targeting of androgen receptor variant enhances response of castration resistant prostate cancer to taxane chemotherapy, Molecular Oncology, 9, 628, 10.1016/j.molonc.2014.10.014

Martin, 2015, Exploitation of the androgen receptor to overcome taxane resistance in advanced prostate cancer, Advances in Cancer Research, 127, 123, 10.1016/bs.acr.2015.03.001

10.1158/0008-5472.CAN-15-2078

10.1124/mol.110.064790

10.1158/1538-7445.AM2013-5066

10.1002/pros.22566

Mellado, 2016, Diving into cabazitaxel’s mode of action: more than a taxane for the treatment of castration-resistant prostate cancer patients, Clinical Genitourinary Cancer, 14, 265, 10.1016/j.clgc.2015.12.030

10.1126/science.aab0917

10.1158/1078-0432.CCR-11-0728

10.1093/emboj/19.3.359

10.1172/JCI66398

10.1158/1535-7163.MCT-14-1057

10.1158/1535-7163.MCT-13-0027

10.1021/jm501239f

10.1073/pnas.1308587110

10.1016/j.eururo.2015.07.007

10.1210/me.2012-1165

10.1021/jm400048v

Qu, 2015, Constitutively active AR-V7 plays an essential role in the development and progression of castration-resistant prostate cancer, Scientific Reports, 5, 7654, 10.1038/srep07654

10.1038/onc.2011.273

10.1016/j.cell.2015.05.001

10.1056/NEJMoa1209096

10.1158/0008-5472.CAN_10-3398

10.1074/jbc.M302460200

10.1056/NEJMoa1207506

10.1016/j.steroids.2012.12.013

Shafi, 2015, Differential regulation of metabolic pathways by androgen receptor (AR) and its constitutively active splice variant, AR-V7, in prostate cancer cells, Oncotarget, 6, 31997, 10.18632/oncotarget.5585

Streicher, 2014, Stilbene induced inhibition of androgen receptor dimerization: implications for AR and ARDeltaLBD-signalling in human prostate cancer cells, PLoS ONE, 9, e98566, 10.1371/journal.pone.0098566

10.1074/jbc.M113.492140

10.1093/carcin/bgv040

10.1172/JCI41824

10.1158/0008-5472.CAN-13-2876

10.1126/science.1168175

10.1242/jcs.096792

van Soest, 2013, Cross-resistance between taxanes and new hormonal agents abiraterone and enzalutamide may affect drug sequence choices in metastatic castration-resistant prostate cancer, European Journal of Cancer, 49, 3821, 10.1016/j.ejca.2013.09.026

10.1379/1466-1268(2002)007<0055:EOGOAR>2.0.CO;2

10.1016/j.molcel.2007.05.041

10.1016/j.cell.2009.04.056

10.1074/jbc.M206061200

10.1073/pnas.1012443107

Welti, 2016, Analytical validation and clinical qualification of a new immunohistochemical assay for androgen receptor splice variant-7 protein expression in metastatic castration-resistant prostate cancer., European Urology, 70, 599, 10.1016/j.eururo.2016.03.049

10.1093/nar/gkt1382

10.1158/0008-5472.CAN-15-0381

10.1158/1078-0432.CCR-14-1108

10.1593/neo.111436

10.1074/jbc.M111.265124

10.1158/1078-0432.CCR-14-0292

10.3390/ijms130911530

10.1002/ijc.28202

10.18632/oncotarget.4396

10.1371/journal.pone.0027970

Zhang, 2016, Regulation of androgen receptor splice variant AR3 by PCGEM1, Oncotarget, 7, 15481, 10.18632/oncotarget.7139

10.1158/0008-5472.CAN-10-0585